Homebiotech

biotech

biotech

Base to Base biotech podcast 56: GRIN genes and relapsing MS

Jim Cornall - April 24, 2026

biotech

Positive first-in-human data for IVF-related embryo implantation failure treatment

Jim Cornall - April 23, 2026

biotech

New company plans to replace daily injections with implant

Jim Cornall - April 23, 2026

biotech

UCB adds epilepsy drug through Neurona Therapeutics acquisition

Jim Cornall - April 23, 2026

AI

Researchers move closer to preventing pandemics

admin - March 31, 2026

biotech

Copper overload kills cancer cells

Jim Cornall - March 31, 2026

biotech

Lyme disease vaccine shows strong efficacy in phase 3 trial

Jim Cornall - March 30, 2026

biotech

FDA approves pill for plaque psoriasis

Jim Cornall - March 30, 2026

biotech

Crossbow Therapeutics raises $77m to treat cancer

Jim Cornall - March 30, 2026

biotech

Base to Base biotech podcast 52: Ketamine for depression, and a new company in the kidney disease space

Jim Cornall - March 27, 2026

biotech

Excalipoint Therapeutics launches with $68.7m to develop T-Cell engager therapies

Jim Cornall - March 26, 2026

biotech

FDA clearance for refractory gout treatment

Jim Cornall - March 26, 2026

1...567...72 Page 6 of 72

Stay Connected

- Advertisement -

spot_img

Latest Articles

biotech

Base to Base biotech podcast 56: GRIN genes and relapsing MS

Jim Cornall - April 24, 2026 0

This week, our conversations are with Bruce Leuchter, co-founder, president, CEO of Neurvati Neurosciences and GRIN Therapeutics; and Daniel Vitt, CEO of Immunic. Base to...

Positive first-in-human data for IVF-related embryo implantation failure treatment

biotech Jim Cornall - April 23, 2026 0

New company plans to replace daily injections with implant

biotech Jim Cornall - April 23, 2026 0

UCB adds epilepsy drug through Neurona Therapeutics acquisition

biotech Jim Cornall - April 23, 2026 0

Mechanism ‘opens new era’ for targeted cancer therapy

biotech Jim Cornall - April 22, 2026 0